Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
BACKGROUND: Staphylococcus aureus remains a common cause of ventilator-associated pneumonia, with little change in incidence over the past 15 years. We aimed to evaluate the efficacy of suvratoxumab, a monoclonal antibody targeting the α toxin, in reducing the incidence of S aureus pneumonia in patients in the intensive care unit (ICU) who are on mechanical ventilation. METHODS: We did a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 31 hospitals in Belgium, the Czech Republic, France, Germany, Greece, Hungary, Portugal, Spain, and Switzerland... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2021 |
Verlag/Hrsg.: |
The Lancet Pub. Group
|
Schlagwörter: | Adolescent / Adult / Aged / Antibodies / Monoclonal / Humanized / Belgium / Broadly Neutralizing Antibodies / Czech Republic / Double-Blind Method / Female / France / Germany / Greece / Humans / Hungary / Lung / Male / Middle Aged / Pilot Projects / Pneumonia / Ventilator-Associated / Portugal / Respiration / Artificial / Spain / Staphylococcal Infections / Staphylococcus aureus / Switzerland / Treatment Outcome / Young Adult |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26573068 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | http://hdl.handle.net/2078.1/259154 |